---
figid: PMC4279367__oncotarget-05-10206-g001
figlink: /pmc/articles/PMC4279367/figure/F1/
number: F1
caption: 'Under physiological conditions, ERK signaling is regulated by extracellular
  signals binding to receptor tyrosine kinases (RTKs). Activated RTKs promote RAS-mediated
  dimerization of RAF; wild-type RAF, as hetero- or homodimers, phosphorylate and
  activate MEK1/2, which in turn phosphorylate and activate ERK1/2. Activated ERK
  promote cell cycle progression and proliferation and negatively regulates upstream
  signaling components (negative feedback). RTKs also regulate the PI3K-AKT-mTOR pathway.
  The two pathways interact at multiple points: most importantly, RAS directly binds
  and activates PI3K.'
pmcid: PMC4279367
papertitle: Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma.
reftext: Francesco Spagnolo, et al. Oncotarget. 2014 Nov;5(21):10206-10221.
pmc_ranked_result_index: '18901'
pathway_score: 0.9448179
filename: oncotarget-05-10206-g001.jpg
figtitle: Under physiological conditions, ERK signaling is regulated by extracellular
  signals binding to receptor tyrosine kinases (RTKs)
year: '2014'
organisms: Homo sapiens
ndex: 25b2506b-deae-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4279367__oncotarget-05-10206-g001.html
  '@type': Dataset
  description: 'Under physiological conditions, ERK signaling is regulated by extracellular
    signals binding to receptor tyrosine kinases (RTKs). Activated RTKs promote RAS-mediated
    dimerization of RAF; wild-type RAF, as hetero- or homodimers, phosphorylate and
    activate MEK1/2, which in turn phosphorylate and activate ERK1/2. Activated ERK
    promote cell cycle progression and proliferation and negatively regulates upstream
    signaling components (negative feedback). RTKs also regulate the PI3K-AKT-mTOR
    pathway. The two pathways interact at multiple points: most importantly, RAS directly
    binds and activates PI3K.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT1
  - NRAS
  - KRAS
  - AKT3
  - NF1
  - PIK3CA
  - BRAF
  - PIK3R4
  - MTOR
  - MAPK1
  - CDKN2A
  - HRAS
  - CDK6
  - PIK3R6
  - MAPK3
  - RB1
  - MAP2K2
  - CCND2
  - PIK3R5
  - MAP2K1
  - AKT2
  - RAF1
  - CCND3
  - PTEN
  - CCND1
  - CDK4
  - PIK3R3
  - PIK3CB
  - ARAF
  - PIK3CG
  - PIK3CD
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: NF1
  symbol: NF1
  source: hgnc_symbol
  hgnc_symbol: NF1
  entrez: '4763'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: p16
  symbol: p16
  source: hgnc_alias_symbol
  hgnc_symbol: CDKN2A
  entrez: '1029'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: CDK4/6
  symbol: CDK6
  source: hgnc_symbol
  hgnc_symbol: CDK6
  entrez: '1021'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: RB1
  symbol: RB1
  source: hgnc_symbol
  hgnc_symbol: RB1
  entrez: '5925'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: CDK4/6|CyclinD
  symbol: Cyclin_D
  source: bioentities_symbol
  hgnc_symbol: CCND2
  entrez: '894'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: CDK4/6|CyclinD
  symbol: Cyclin_D
  source: bioentities_symbol
  hgnc_symbol: CCND3
  entrez: '896'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: CDK4/6|CyclinD
  symbol: Cyclin_D
  source: bioentities_symbol
  hgnc_symbol: CCND1
  entrez: '595'
- word: CDK4/6|CyclinD
  symbol: CDK4
  source: hgnc_symbol
  hgnc_symbol: CDK4
  entrez: '1019'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC4279367__F1
redirect_from: /figures/PMC4279367__F1
figtype: Figure
---
